UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

UCLA Pathology & Laboratory Medicine


Clinical Microarray Core | CMC




The first new generation of Illumina sequencer, HiSeq3000, is now available at UCLA Clinical Microarray Core. To help investigators quickly experience the power and potential of this low cost, fast TAT and high throughput sequencing system, we are offering an introductory price in November, 2015 for HiSeq3000 sequencing as below:
1) RNAseq: $350/sample including QC, library construction and 1x50 sequencing (need at least 24 samples, deliver >12 million reads)
2) whole exome sequencing for germline mutations: $650/exome including QC, library construction/exome enrichment and 2x150 sequencing (need at least 12 samples, deliver >50 million PE reads)
3) whole exome sequencing for somatic mutations: $850/exome including QC, library construction/exome enrichment and 2x150 sequencing (need at least 6 samples, deliver >100 million PE reads)
This introductory price is for limited time only. For more information, please contact Dr. Xinmin Li    XinminLi@mednet.ucla.edu

06/04/2015 UCLA CMC is pleased to announce a 4-day Next Generation Sequencing Workshop to be held on July 13-16, 2015. Register here.


The UCLA Clinical Microarray Core (CMC) is a CAP-accredited, fully automated, high-throughput genomic facility equipped with all major next generation sequencing and microarray platforms.  The CMC provides these services in a cost-effective and timely manner to serve basic science, translational, and clinical researchers.  In addition, the CMC provides pre-experiment consultation and post-experiment support, including preparation of grant applications, publications, and strategic planning for additional research steps.  The CMC also provides educational training to faculty, staff, and students to raise awareness on new directions and major discoveries in the areas of genomics and bioinformatics.    

Goals & Mission

  1. To provide next generation sequencing and microarray-based genomic services to the research community.
  2. To develop and maintain the highest quality and reliability for the genomic services that we offer. 
  3. To lead in establishing quality standards for genomic services (e.g., sample processing, data analysis and interpretation).
  4. To advance the relatively new specialty area of personalized medicine through education, research, and publications.


UCLA Rated One of the Top Hospitals in the Nation